In a much-anticipated decision in Association for Molecular Pathology v. Myriad Genetics, Inc., the United States Supreme Court has held that product claims directed to naturally occurring BRCA gene sequences are products of nature and are therefore not eligible for patent protection.  Thus claims to naturally occurring nucleic acids are not … Continue reading Why Patent Attorneys are indispensable / Are third parties free to produce Myriad’s breast cancer gene test?Read More »